Full-Time
Maintenance Mechanic
Blue Industries
Genetic health diagnostics and COVID testing
Compensation Overview
$40/hr
North Brunswick Township, NJ, USA
In Person
 General Maintenance & Repair (1) |
|---|
Get referred to Blue Industries
See people who can refer or advise you
- Basic mechanical knowledge and hands-on experience.
- Ability to perform oil changes, tire rotations, and general maintenance tasks independently.
- Strong attention to detail and problem-solving skills.
- Ability to lift up to 50 pounds and perform physical work.
- Reliability and punctuality with a strong work ethic.
- Perform routine vehicle maintenance, including oil changes and tire rotations.
- Inspect vehicles for wear and potential mechanical issues.
- Maintain service records and report needed repairs.
- Check and top off fluids, including oil, coolant, and brake fluid.
- Ensure tires are properly inflated and in safe condition.
- Assist with basic repairs and preventative maintenance tasks.
- Keep the shop and work area clean, organized, and safe.
- Follow all safety procedures and company guidelines.
- Experience working with diesel vehicles is preferred.
- Previous experience in a mechanic or automotive maintenance role is preferred.
- Familiarity with fleet maintenance is preferred.
Blue Industries provides health diagnostics and genetic analysis for individuals and corporate clients, using genetic data to predict health risks and COVID-19 severity risk. It analyzes genetic information with bioinformatics and material science to power online diagnostic platforms delivered via service fees. The company differentiates itself by prioritizing data security, regulatory compliance, and an online-first delivery model for both personal and business customers. Its goal is to offer practical, actionable health insights while protecting personal data and meeting legal standards.
Company Size
N/A
Company Stage
Late Stage VC
Total Funding
$950K
Headquarters
Tokyo, Japan
Founded
2015
Get referred to Blue Industries
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 GeneQuest deal expands Blue's cross-sell base and data moat.
- GeneQuest's 2014 service history brings established demand and credibility to Blue.
- Blue now controls a broader preventive-care pathway from genetic insight to screening behavior.
What critics are saying
- Bluedrop remains a risk indicator, not diagnosis, limiting clinician adoption through 2027.
- GeneQuest integration concentrates sensitive genomic data, raising breach and compliance exposure immediately.
- If regulators challenge predictive cancer claims, Blue's consumer diagnostics story collapses quickly.
What makes Blue Industries unique
- August 1, 2026 acquisition of GeneQuest adds 360-trait genetic testing depth.
- Bluedrop links urine miRNA cancer risk screening with inherited-risk genetics in one funnel.
- Blue Industries combines AI, bioinformatics, and consumer diagnostics across home and corporate channels.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Company News
Blue Industries has acquired all shares of GeneQuest, making it a wholly owned subsidiary effective 1 August 2026. The acquisition was completed through a purchase from Euglena Company. Blue Industries develops Bluedrop, a home-use cancer risk assessment kit that analyses microRNA patterns in urine to evaluate risks for seven types of cancer. GeneQuest has provided genetic testing services since 2014, offering analysis of over 360 hereditary traits including disease risks and physical characteristics. The acquisition aims to create an integrated healthcare pathway combining GeneQuest's genetic analysis with Blue Industries' current cancer risk assessment technology. This will enable users to understand both their inherited disease predispositions and current cancer risks, supporting appropriate screening and medical consultation. GeneQuest's existing management team, led by CEO Osamu Iwata, will continue, with Blue Industries' representatives joining the board. GeneQuest's headquarters will relocate to Blue Industries' office in Tokyo's Chuo ward.